Perampanel may reduce alpha-synuclein transmission in Parkinson's disease. A possible therapeutic target?

MDS Podcast

Content provided by International Parkinson and Movement Disorder Society, International Parkinson, and Movement Disorder Society. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by International Parkinson and Movement Disorder Society, International Parkinson, and Movement Disorder Society or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

2+ y ago 14:26

MP3

Archived series ("Inactive feed" status)

When? This feed was archived on May 02, 2022 04:09 (2y ago). Last successful fetch was on March 28, 2022 22:54 (2y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Dr. Matarazzo speaks with Prof. Takahashi about the results of his recent study that shows how this anti-epileptic drug may inhibit the transmission of alpha synuclein in PD. While this was tested in animal models, future clinical trials are warranted to test the effects on PD progression. Read the article

58 episodes

#Neurology #International Parkinson and Movement Disorder Society #International Parkinson #Movement Disorder Society #Science #Medicine #RSS Feed